Table 3ESAs, approval status, and approved starting dose

ESAApproval Status U.S.Approval Status European UnionApproved Dose
Epoetin alfaEPOGEN® (Amgen)

PROCRIT® (Ortho Biotech)
Eprex® (Janssen-Cilag)Epoetin alfa preparations are formulated for IV or SC administration. The recommended adult starting dose is 150 Units/kg SC 3 times per week or 40,000 Units SC weekly. Dose may be modified depending on Hb response.
Darbepoetin alfaAranesp® (Amgen)Aranesp® (Amgen)Aranesp® is formulated for IV or SC administration. The recommended initial adult dose is either 2.25 mcg/kg SC weekly or 500 mcg SC every 3 weeks. Dose may be modified depending on Hb response.
Epoetin betaNot approved for use in the U.S.*NeoRecormon® (Hoffmann-La Roche)NeoRecormon® is formulated for IV or SC administration. The recommended initial dose is 30,000 IU per week given as one injection per week or in divided doses 3 to 7 times per week. Dose may be modified depending on Hb response.

ESA = erythropoietic-stimulating agent; Hb = hemoglobin; IV = intravenous; IU = international unit; kg = kilogram; mcg = microgram; SC = subcutaneous

*

See also Background. While not approved in the United States, effects are considered exchangeable with epoetin alfa.

From: Introduction

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.